Nonalcoholic Fatty Liver Disease and Cardiovascular Disease - PubMed (original) (raw)

Review

. 2021 Feb 1;17(1):19-22.

doi: 10.1002/cld.1017. eCollection 2021 Jan.

Affiliations

Review

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease

Eric M Przybyszewski et al. Clin Liver Dis (Hoboken). 2021.

Abstract

Watch a video presentation of this article Answer questions and earn CME.

© 2021 by the American Association for the Study of Liver Diseases.

PubMed Disclaimer

Figures

FIG 1

FIG 1

Pathogenesis of Cardiovascular Disease in NAFLD. NAFLD contributes to cardiovascular disease risk through dyslipidemia, insulin resistance, altered coagulation states and increased inflammation.

References

    1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction–associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202‐209. - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease: meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73‐84. - PubMed
    1. Targher G, Byrne CD, Lonardo A, et al. Non‐alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta‐analysis. J Hepatol 2016;65:589‐600. - PubMed
    1. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579‐1584. - PMC - PubMed
    1. DeFilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi‐Ethnic Study of Atherosclerosis. Atherosclerosis 2013;227:429‐436. - PMC - PubMed

Publication types

LinkOut - more resources